Fresenius Medical Care AG & Co. (NYSE:FMS) and EHang (NASDAQ:OTRK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.
Valuation & Earnings
This table compares Fresenius Medical Care AG & Co. and EHang’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fresenius Medical Care AG & Co.||$19.58 billion||1.34||$1.34 billion||$2.53||17.33|
|EHang||$35.10 million||18.55||-$25.66 million||($1.15)||-33.27|
Fresenius Medical Care AG & Co. has higher revenue and earnings than EHang. EHang is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co., indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
1.5% of Fresenius Medical Care AG & Co. shares are owned by institutional investors. Comparatively, 20.0% of EHang shares are owned by institutional investors. 58.2% of EHang shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Fresenius Medical Care AG & Co. has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, EHang has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500.
This table compares Fresenius Medical Care AG & Co. and EHang’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Fresenius Medical Care AG & Co.||7.26%||10.47%||4.19%|
This is a summary of current ratings for Fresenius Medical Care AG & Co. and EHang, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Fresenius Medical Care AG & Co.||0||3||9||1||2.85|
Fresenius Medical Care AG & Co. currently has a consensus target price of $45.13, suggesting a potential upside of 2.91%. Given Fresenius Medical Care AG & Co.’s higher probable upside, research analysts clearly believe Fresenius Medical Care AG & Co. is more favorable than EHang.
Fresenius Medical Care AG & Co. beats EHang on 10 of the 15 factors compared between the two stocks.
Fresenius Medical Care AG & Co. Company Profile
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2018, it operated 3,928 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
EHang Company Profile
Ontrak, Inc. operates as an artificial intelligence powered, virtualized outpatient healthcare treatment company that provides in-person or telehealth intervention services to health plans and other third-party payors. Its Ontrak PRE (Predict-Recommend-Engage) platform predicts people whose chronic disease will improve with behavior change, recommends care pathways that people are willing to follow, and engages people who aren't getting the care they need. The company's technology-enabled, OnTrak, program is designed to treat health plan members with unaddressed behavioral health conditions that cause or exacerbate chronic medical diseases, such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was founded in 2003 and is headquartered in Santa Monica, California.
Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.